STOCK TITAN

MDxHealth Q3 2026 net loss rises 26% to $12.3M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

MDxHealth SA (MDXH) reported third-quarter 2026 continuing-operations revenue of $22.7 million, flat year over year. Gross profit was $14.0 million, down 5%, and the net loss increased 26% to $12.3 million from $9.7 million. Adjusted EBITDA was a loss of $6.3 million, compared with a $0.9 million loss a year earlier. Results exclude Resolve mdx, classified as a discontinued operation.

For the first nine months, revenue rose 9% to $73.8 million, while net loss increased 21% to $31.4 million. Adjusted EBITDA was a loss of $13.9 million, versus $0.9 million. Cash and cash equivalents were $31.7 million as of September 30, 2026.

The company eliminated the Chief Commercial Officer position, and John Bellano’s employment ended October 23, 2026. Sales and marketing now report directly to CEO Michael K. McGarrity. Management expects to exit the fourth quarter with a fully staffed, trained sales organization positioned to return to growth in 2027; it also said strategic AI initiatives are planned for the first half of 2027.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 4 points

How the balance works

Positive

  • Moderate pointNine-month revenue rose 9% to $73.8 million.

Negative

  • Moderate pointNine-month net loss increased 21% to $31.4 million.
  • Moderate pointNine-month adjusted EBITDA was a $13.9 million loss, versus $0.9 million.
  • Moderate pointOperating cash outflow was $10.6 million, compared with $2.6 million.
  • Minor pointThird-quarter net loss increased 26% to $12.3 million.

Filing Explained

At September 30, 2026, loans and borrowings were $96,849 thousand; share issuance generated $20,000 thousand net during the first nine months of 2026.

MDxHealth reports that share issuance during the first nine months of 2026 generated $20,000 thousand net of transaction costs. Issuing additional shares increases the total share count and reduces existing holders’ percentage ownership absent offsetting changes.

The cash-flow statement also reports $19,400 thousand in loan proceeds during the first nine months of 2026. Loans and borrowings were $96,849 thousand at September 30, 2026, versus $76,197 thousand at December 31, 2025.

Third-quarter revenue $22.7 million Three months ended September 30, 2026; flat year over year.
Nine-month revenue $73.8 million Nine months ended September 30, 2026; up 9% from $67.7 million.
Third-quarter net loss $12.3 million loss Three months ended September 30, 2026; up 26% from $9.7 million.
Third-quarter adjusted EBITDA $6.3 million loss Three months ended September 30, 2026; compared with a $0.9 million loss in 2025.
Nine-month net loss $31.4 million loss Nine months ended September 30, 2026; up 21% from $26.0 million.
Nine-month adjusted EBITDA $13.9 million loss Nine months ended September 30, 2026; compared with a $0.9 million loss in 2025.
Cash and cash equivalents $31.7 million As of September 30, 2026.
Operating cash outflow $10.6 million Nine months ended September 30, 2026; compared with $2.6 million in 2025.
continuing operations financial
"Financial review of continuing operations"
Continuing operations are the parts of a company's business that it expects to keep running into the future, excluding divisions or activities it has sold, closed, or classified as discontinued. Investors watch continuing operations because they show the company’s core ability to generate revenue and profit over time — like evaluating the healthy, ongoing crops on a farm rather than one-off harvests from fields you've already sold.
discontinued operation financial
"classified as a discontinued operation in accordance with IFRS"
A discontinued operation is a part of a company that has been sold, closed, or is planned to be shut down, and will no longer be part of its ongoing business activities. For investors, it matters because it can significantly affect a company's financial results and future outlook, similar to removing a large, ongoing project from a company's operations. Recognizing discontinued operations helps investors better understand a company's current performance separate from parts that are no longer active.
Adjusted EBITDA financial
"Adjusted EBITDA and adjusted EBITDA margin"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
gross margins financial
"Gross margins were 61.8%"
Gross margins measure the portion of sales a company keeps after paying the direct costs to make its products or deliver services, expressed as a percentage of revenue. Think of it as the money left from each sale after paying the ingredients — it signals how efficiently a business produces and prices goods, and matters to investors because higher margins generally mean more room to cover other expenses, invest, and generate profit.
fair-value adjustments financial
"Fair value adjustments"
Changes made to the recorded value of an asset or liability so its carrying amount on the financial statements equals its fair value as defined by accounting standards. These adjustments arise when an item is remeasured using market-based inputs or valuation techniques and are recognized either in profit or loss or in other comprehensive income depending on the accounting classification of the item; the measurement relies on observable market prices when available and on judgment-based valuation models when not, which are categorized by input level (Level 1–3).
PROTECT study medical
"advance our landmark PROTECT study with the University of Oxford"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did MDXH report in Q3 2026?

MDxHealth reported third-quarter 2026 revenue from continuing operations of $22.7 million, flat compared with the prior-year quarter. The reported results exclude Resolve mdx, which is classified as a discontinued operation.

When does MDXH expect to launch its AI initiatives?

Management said it was preparing to roll out strategic AI initiatives in the first half of 2027. The company also said it was advancing the PROTECT study with the University of Oxford.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number 001-40996

 

MDXHEALTH SA

(Translation of registrant’s name into English)

 

CAP Business Center

Zone Industrielle des Hauts-Sarts

4040 Herstal, Belgium

+32 4 257 70 21

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

 

  

MDXHEALTH SA

 

On November 6, 2028, Eric Bednarski resigned from the board of directors (the “Board”) of MDxHealth SA (the “Company”) effective immediately. The decision of Mr. Bednarski to resign did not result from any disagreement with the Company on any matters relating to the Company’s operations, policies, or practices.

 

As part of a restructuring of its commercial organization, the Company eliminated the position of Chief Commercial Officer. Accordingly, John Bellano's employment with the Company ended effective October 23, 2026. The Company's sales and marketing functions now report directly to Michael K. McGarrity, the Company's Chief Executive Officer.

 

On November 12, 2026, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1.

 

Information Incorporated by Reference

 

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-292463 and 333-280606) and Form S-8 (Registration No. 333-294873) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished; provided, however, the information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

Exhibit No.   Description of Exhibit
99.1   Press Release, dated November 12, 2026

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MDXHEALTH SA
     
Date: November 12, 2026 By: /s/ Michael McGarrity
    Name:  Michael McGarrity
    Title: Chief Executive Officer

 

2

 

 

 

Exhibit 99.1

 

Mdxhealth Reports Third Quarter 2026 Financial Results

 

Conference call with Q&A today at 4:30 PM EST / 22:30 CET

 

IRVINE, Calif. – November 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leader in urology-focused precision diagnostics, today announced its financial results for the third quarter ended September 30, 2026.

 

Michael K. McGarrity, CEO of mdxhealth, commented: “As we communicated in our October preliminary update, our third quarter results reflect a temporary disruption in our commercial execution due to accelerated turnover within our sales organization. In direct response, we have initiated a restructuring of our commercial organization to reset our focus and process across our sales, marketing, and client services groups. By eliminating the Chief Commercial Officer role and effectively splitting our sales and marketing functions – both of which now report directly to me – we have established a vital check and balance on what had become a vertical operating structure, driving clear delineation and direct accountability for product strategy and sales execution while enhancing our customer experience.

 

“We have already made considerable progress in backfilling and rebuilding our sales team, and we are highly encouraged by the caliber of talent and industry experience we are attracting to mdxhealth. With selection, development, and retention serving as the foundation of our process through this commercial reset, we expect to exit the fourth quarter with a fully staffed and well-trained sales organization positioned to return to growth in 2027.

 

“We are confident that this commercial reset is both necessary and timely as we continue to advance our landmark PROTECT study with the University of Oxford and prepare to roll out our strategic AI initiatives in the first half of 2027. Supported by our operating teams’ mandate of ‘Quality First and Customers Always,’ we remain committed to returning to the exemplary level of sales execution that has been the hallmark of our results over the last four years. Coupled with our proven track record of operating discipline, we are well-positioned to return mdxhealth to sustainable growth and adjusted EBITDA profitability as we continue to build on our unmatched vertical of clinically actionable precision diagnostics for our customers and patients in urologic cancers.”

 

Key Highlights for the third quarter from continuing operations:

 

●Revenue of $22.7 million versus same revenue for the prior year period

 

●Operating loss of $8.1 million compared to $4.4 million for third quarter of 2025, primarily due to increased operating expenses related to the ExoDx acquisition

 

●Net loss of $12.3 million, an increase of 26% over prior year period

 

●Adjusted EBITDA of ($6.3) million compared to ($0.9) million for the same period last year

 

●Tissue-based (Confirm mdx and GPS mdx) test volume of 11,232, a decrease of 11% over prior year period

 

●Liquid-based (Exo mdx) test volume of 11,792 compared to Select mdx volume of 4,600 for the same period last year

 

●Period-end cash and cash equivalents balance of $31.7 million

 

Results exclude Resolve mdx, which has been discontinued and accounted for as a “discontinued operation” for the current and prior year periods.

 

 

 

 

Discontinuation of the Resolve mdx Business

 

As previously announced in our first quarter 2026 update, the Company made the strategic decision to discontinue the Resolve UTI offering to renew our focus on our core prostate cancer business. We successfully completed this wind-down in Q2, with the permanent cessation of operations of our wholly-owned subsidiary Delta Laboratories, LLC and its Plano, Texas laboratory prior to June 30, 2026. Having met the requisite accounting criteria, the Resolve business is now formally classified as a discontinued operation in accordance with IFRS. As required by these reporting standards, all current and prior-year financial metrics discussed in this release and related financial statements reflect only our continuing core operations, with the historical results of the Resolve business fully excluded.

 

Financial review of continuing operations for the three and nine months ended, September 30, 2026 and 2025

 

  Three months ended September 30   Nine months ended September 30 
USD in ’000 (except per share data) Unaudited  2026   2025 (re-presented*)   % Change   2026   2025 (re-presented*)   % Change 
Revenue   22,711       22,728    0%   73,817       67,685    9%
Cost of sales (exclusive of amortization of intangible assets)   (8,675)   (7,966)   9%   (27,222)   (22,404)   22%
Gross Profit   14,036    14,762    (5)%   46,595    45,281    3%
Operating expenses   (22,164)   (19,130)   16%   (67,986)   (55,865)   22%
Operating loss   (8,128)   (4,368)   86%   (21,391)   (10,584)   102%
Net loss   (12,259)   (9,736)   26%   (31,433)   (25,998)   21%
Adjusted EBITDA**   (6,281)   (912)   n/a    (13,914)   (914)   n/a 
Basic and diluted loss per share   (0.16)   (0.20)   (20%)   (0.53)   (0.52)   2%

  

*Comparative information has been re-presented to reflect the classification of the Resolve business as a discontinued operation

**A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading “Non-IFRS Measures”

 

Results from continuing operations for the three months ended September 30, 2026

 

Revenue was flat compared to the prior year at $22.7 million. Revenue in the third quarter of 2026 and 2025 was comprised of 79% and 92% from tissue-based tests, respectively.

 

Gross profit decreased 5% to $14.0 million compared to $14.8 million for the prior year. Gross margins were 61.8% as compared to 65.0% for the prior year, a reduction of 3.2 percentage points, primarily attributed to test mix.

 

Operating loss increased 86% to $8.1 million compared to $4.4 million for the prior year, driven by increased operating expenses related to the ExoDx acquisition in September 2025.

 

Net loss increased 26% to $12.3 million compared to $9.7 million for the prior year, primarily driven by higher operating expenses related to the ExoDx acquisition in September 2025.

 

Adjusted EBITDA was ($6.3) million compared to ($0.9) million for the same period last year.

 

A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading “Non-IFRS Disclosure.”

 

2

 

 

Results from continuing operations for the nine months ended September 30, 2026

 

Revenue increased 9% to $73.8 million compared to $67.7 million for the prior year. Revenue in the first nine months of 2026 and 2025 was comprised of 76% and 95% from tissue-based tests, respectively.

 

Gross profit increased 3% to $46.6 million compared to $45.3 million for the prior year. Gross margins were 63.1% as compared to 66.9% for the prior year, a reduction of 3.8 percentage points, primarily attributed to test mix.

 

Operating loss increased 102% to $21.4 million compared to $10.6 million for the prior year, driven by increased operating expenses related to the ExoDx acquisition in September 2025.

 

Net loss increased 21% to $31.4 million compared to $26.0 million for the prior year, primarily driven by higher operating expenses related to the ExoDx acquisition in September 2025.

 

Adjusted EBITDA was ($13.9) million compared to ($0.9) million for the same period last year.

 

A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading “Non-IFRS Disclosure.”

 

Cash and cash equivalents as of September 30, 2026, were $31.7 million.

 

Conference Call

 

Michael K. McGarrity, Chief Executive Officer, and Ron Kalfus, Interim Chief Financial Officer, will host a conference call and Q&A session today at 4:30 PM EST / 22:30 CET. The call will be conducted in English and a replay will be available for 30 days.

 

To participate in the conference call, please select your phone number below:

 

United States: 1-800-347-6865

 

Belgium: 0800 72 519

 

United Kingdom: 0808 101 1183

 

Conference ID: MDX3Q26

 

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1778654&tp_key=d6263296bf

 

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled

start time.

 

About mdxhealth

 

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

 

3

 

 

Non-IFRS disclosure

 

In addition to the Company’s financial results determined in accordance with IFRS, the Company provides adjusted EBITDA and adjusted EBITDA margin, non-IFRS measures that the Company determines to be useful in evaluating its operating performance. The Company defines adjusted EBITDA as net loss from continuing operations less interest expense, depreciation and amortization of intangible assets, impairment, share-based compensation, fair-value adjustments, provision for inventory obsolescence, reduction in force severance costs, ExoDx acquisition expenses, amendments related to the Exact Sciences earnout, income tax benefit (expense), and other financial and non-cash expenses. Management believes that presentation of non-IFRS financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenue. The Company uses this non-IFRS financial information to establish budgets, manage the Company’s business, and set incentive and compensation arrangements. However, non-IFRS financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS. For example, non-IFRS adjusted EBITDA excludes a number of expense items that are included in net loss. As a result, positive adjusted EBITDA may be achieved while a significant net loss persists. The Company’s presentation of expected non-IFRS adjusted EBITDA is a forward-looking statement about the Company’s future financial performance. This non-IFRS measure includes adjustments like share-based compensation, debt extinguishment costs, fair-value adjustments related to contingent considerations that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Additionally, management does not forecast many of the excluded items for internal use. Information reconciling forward-looking non-IFRS measures to IFRS measures is therefore not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of the items excluded from IFRS to calculate non-IFRS could significantly impact the Company’s IFRS results.

 

Forward-Looking Statement: This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding the Company’s unaudited financial results for the third quarter of 2026; expected future operating results; our strategies, positioning, resources, capabilities, market opportunities and expectations for future events or performance; and the anticipated timing and benefits of our organizational changes and strategic initiatives. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; our ability to recruit, train and retain qualified sales personnel and the time required for new sales personnel to reach full productivity the acceptance of our products and services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; changes in payer claims reimbursement practices and MDxHealth estimates regarding collection amounts for tests; the results of recoupment decisions and related appeals; the impacts and effectiveness of exiting from discontinued operations; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash will be sufficient to fund our future operating expenses and capital expenditure requirements; our ability to remain in compliance with financial covenants made to and make scheduled payments to our creditors; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the ExoDx and GPS prostate cancer businesses will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

 

NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS mdx, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate Intelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of MDxHealth SA and its affiliates. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark and all other trademarks and service marks, are the property of their respective owners.

 

4

 

 

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

 

   Three months ended   Nine months ended 
   September 30,   September 30, 
       2025       2025 
Thousands of $ (except per share data)  2026   (re-presented*)   2026   (re-presented*) 
–Continuing operations–                
Revenues   22,711         22,728    73,817         67,685 
Cost of sales (exclusive of amortization of intangible assets)   (8,675)   (7,966)   (27,222)   (22,404)
Gross profit   14,036    14,762    46,595    45,281 
Research and development expenses   (2,406)   (2,006)   (6,535)   (6,353)
Selling and marketing expenses   (11,693)   (9,458)   (34,497)   (27,274)
General and administrative expenses   (7,485)   (7,211)   (23,720)   (19,110)
Amortization of intangible assets   (1,246)   (1,289)   (3,759)   (3,915)
Other operating (expense) income, net   666    834    525    787 
Operating loss   (8,128)   (4,368)   (21,391)   (10,584)
Financial income   1,037    502    2,409    1,371 
Financial expenses   (5,168)   (5,876)   (12,451)   (17,070)
Loss before income tax   (12,259)   (9,742)   (31,433)   (26,283)
Income tax benefit   0    6    0    285 
Loss from continuing operations   (12,259)   (9,736)   (31,433)   (25,998)
–Discontinued operations–                    
Loss from discontinued operations, net of tax   (2,054)   1,726    (3,279)   1,407 
Loss for the period attributable to owners of the parent   (14,313)   (8,010)   (34,712)   (24,591)
                     
Loss per share attributable to owners of the parent                    
Basic and diluted loss per share from continuing operations   (0.16)   (0.20)   (0.53)   (0.52)
Basic and diluted loss per share from discontinued operations   (0.03)   0.03    (0.06)   0.02 
Total basic and diluted loss per share   (0.19)   (0.16)   (0.59)   (0.50)

 

*Comparative information has been re-presented to reflect the classification of the Resolve business as a discontinued operation.

 

5

 

 

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 

Thousands of $  As of
September 30,
2026
   As of
December 31,
2025
 
ASSETS        
Non-current assets        
Goodwill   39,216    38,948 
Intangible assets   35,312    39,424 
Property, plant and equipment   3,019    4,855 
Right-of-use assets   7,641    9,821 
Financial assets   2,029    1,496 
Total non-current assets   87,217    94,544 
           
Current assets          
Assets held-for-sale   0    940 
Inventories   7,171    6,741 
Trade receivables   11,887    14,675 
Prepaid expenses and other current assets   1,925    2,021 
Cash and cash equivalents   31,711    29,032 
Total current assets   52,694    53,409 
TOTAL ASSETS   139,911    147,953 
           
EQUITY          
Share capital   239,028    219,209 
Issuance premium   153,177    153,177 
Accumulated deficit   (437,746)   (403,034)
Share-based compensation   21,739    19,335 
Translation reserve   (740)   (781)
Total equity   (24,542)   (12,094)
           
LIABILITIES          
Non-current liabilities          
Loans and borrowings   96,849    76,197 
Lease liabilities   7,034    8,509 
Other non-current financial liabilities   19,279    25,807 
Total non-current liabilities   123,162    110,513 
           
Current liabilities          
Loans and borrowings   0    0 
Lease liabilities   1,707    1,898 
Trade payables   12,140    10,330 
Other current liabilities   7,121    6,741 
Other current financial liabilities   20,323    30,565 
Total current liabilities   41,291    49,534 
Total liabilities   164,453    160,047 
TOTAL EQUITY AND LIABILITIES   139,911    147,953 

 

6

 

 

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

 

Thousands of $        
For the nine months ended September 30,  2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES        
Operating loss   (22,624)   (9,146)
Depreciation   3,189    2,828 
Amortization of intangible assets   3,775    3,939 
Impairment   1,065    0 
Provision for inventory obsolescence   901    794 
Share-based compensation   1,608    1,518 
Other non-cash transactions   (664)   (853)
Cash used in operations before working capital changes   (12,750)   (920)
           
Changes in operating assets and liabilities          
Increase (-) in inventories   (1,407)   (1,383)
Increase (-) in receivables   1,428    (538)
Increase (+) decrease (-) in payables   2,164    274 
Net cash outflow from operating activities   (10,565)   (2,567)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property, plant and equipment   (710)   (1,103)
Payment of ExoDx purchase price adjustment   (323)   0 
Payment to Bio-Techne for share of Innovation Platform sale proceeds   (329)   755 
Earnout payment (GPS acquisition)   (7,479)   (21,252)
Transfer of cash due to deconsolidation of Delta Laboratories   (286)   0 
Interest received   537    1,249 
Net cash outflow from investing activities   (8,590)   (20,351)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from issuance of shares, net of transaction costs   20,000    0 
Proceeds from loan obligation   19,400    24,250 
Earnout payment (GPS acquisition)   (6,521)   (6,719)
Repayment of PPP loan obligation   0    (324)
Payment of lease liability   (2,080)   (1,570)
Payment of interest   (8,613)   (7,175)
Other financial expense   (351)   (344)
Net cash inflow from financing activities   21,835    8,118 
           
Net decrease in cash and cash equivalents   2,680    (14,800)
           
Cash and cash equivalents at beginning of the period   29,032    46,798 
Effect of exchange rates   (1)   16 
Cash and cash equivalents at end of the period   31,711    32,014 

 

7

 

 

UNAUDITED RECONCILIATION OF IFRS TO NON-IFRS FINANCIAL MEASURES

 

   Three months ended   Nine months ended 
   September 30,   September 30, 
       2025       2025 
Thousands of $  2026   (re-presented*)   2026   (re-presented*) 
                 
IFRS net loss from continuing operations   (12,259)        (9,736)   (31,433)        (25,998)
Amortization of intangible assets   1,246    1,289    3,759    3,915 
Depreciation expense   777    827    2,769    2,395 
Impairment   0    367    0    367 
Interest expense, net   3,593    2,816    9,944    7,299 
Share-based compensation expense   441    447    1,608    1,518 
Reduction in force severance costs   0    (16)   0    335 
Income tax expense   0    (6)   0    (285)
ExoDx acquisition expenses   0    1,566    0    1,566 
Fair value adjustments (1)   416    2,100    (295)   7,735 
Other adjustments (2)   (495)   (566)   (266)   239 
Adjusted EBITDA   (6,281)   (912)   (13,914)   (914)

 

*Comparative information has been re-presented to reflect the classification of the Resolve business as a discontinued operation.

1)Primarily related to GPS and ExoDx contingent considerations, option to pay Bio-Techne and Exact Sciences contingent considerations in shares, and Exact Sciences 5-year warrants

2)Bank fees and other non-cash expenses

 

For more information:

 

info@mdxhealth.com

 

LifeSci Advisors (IR & PR)

John Fraunces

Managing Director

Tel: +1 917 355 2395

Jfraunces@lifesciadvisors.com 

 

8

 

 

Filing Exhibits & Attachments

1 document

Keep reading